We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Evrysdi

News List

EMA accepts marketing application for Spinal Muscular Atrophy treatment europeanpharmaceuticalreview
August 20, 2020
The European Medicines Agency (EMA) has accepted the marketing authorisation application for Evrysdi™ (risdiplam) as a treatment of spinal muscular atrophy (SMA).
Roche gets US FDA approval for Evrysdi to treat spinal muscular atrophy expresspharma
August 12, 2020
In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA.
Roche gets FDA nod for Evrysdi to treat spinal muscular atrophy pharmaceutical-business-review
August 11, 2020
Roche has secured approval from the US Food and Drug Administration (FDA) for its Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in adults and children aged two months of age and older.
Genentech secures FDA approval for Evrysdi to treat SMA pharmaceutical-technology
August 11, 2020
Roche unit Genentech has received approval from the US Food and Drug Administration (FDA) for Evrysdi (risdiplam) to treat spinal muscular atrophy (SMA) in patients aged two months and above.

Previous page 1 2 Next page